Post–CAR T relapse in MCL is associated with median PFS ~2.5 months and OS ~5.4 months, underscoring a high-need salvage setting without an established standard. Relapse biopsy demonstrated retained ...
Phase 2 data show promising antiviral activity with tobevibart plus elebsiran in hepatitis D, supporting further evaluation in the phase 3 ECLIPSE program. First identified in the late 1970s by ...
A recent JAMA Dermatology analysis refines mild-moderate-severe cutoffs for vitiligo, but Dr. Desai and Dr. Lal argue that psychosocial burden, anatomic site, and cultural context can make even ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results